X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2021 16:01 ET
|
X4 Pharmaceuticals
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021
April 22, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing
March 19, 2021 08:01 ET
|
X4 Pharmaceuticals
BOSTON, March 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 04, 2021 08:00 ET
|
X4 Pharmaceuticals
2021 expected to be a year of key value-driving catalysts as company advances multiple clinical programs with lead candidate mavorixafor Company anticipates completing full enrollment in WHIM Phase 3...
X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021
February 11, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Feb. 02, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference
January 19, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference
January 07, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...